Eli Lilly (NYSE:LLY)
Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Dave Sebastian
Eli Lilly and Co. (LLY) said it has started its first Phase 3 trial for selpercatinib on non-small cell lung cancer patients who haven't undergone treatment for metastatic disease.
The company said the trial aims to enroll 400 patients, who will receive either selpercatinib, also known as Loxo-292, or platinum-based and pemetrexed therapy with or without pembrolizumab as initial treatment.
Selpercatinib is an oral drug that aims to treat cancers with abnormalities in the rearranged during transfection kinase, Lilly said.
Write to Dave Sebastian at firstname.lastname@example.org
(END) Dow Jones Newswires
December 11, 2019 07:12 ET (12:12 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.